With an income increase of 200.85% in the first quarter 2026, year on year to cumulative value of $20 million, and with 14 employees, Xoma Royalty's income per employee grew on trailing twelve month basis to $ 1,423,714. The income per employee at Xoma Royalty' was above the company average.
The Healthcare sector has seen employees of 14 other companies achieving higher income per employee. While Xoma Royalty's total ranking has deteriorated compared to the previous quarter from 127 to 149.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

XOMA Net Income per Employee	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Net Income Change	200.85 %	-	-	-45.99 %	-
Net Income per Employee (TTM) $	1,423,714	1,322,571	921,214	-1,049,643	-713,786
XOMA's Total Ranking	# 149	# 127	# 190	# 3290	# 2778
Seq. Net Income Change	-35.88 %	-63.17 %	62.64 %	683.26 %	-

XOMA Company Profile >> Back to XOMA Efficiency Comparisons >> Compare XOMA Net Income per Employee to its Competitors

XOMA Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 15
Healthcare Sector	# 20
Overall Market	# 149

Net Income per Employee Statistics
High	Average	Low
$ 2,105,786	$ -1,654,019	$ -8,861,286
(Dec 31 2021)		(Dec 31 2013)

Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Mar 31 2026	Number of Employees Mar 31 2026
Aurinia Pharmaceuticals Inc	2,329,789.06	$ 298.213 Million	128
Rigel Pharmaceuticals Inc	2,093,287.36	$ 364.232 Million	174
Quince Therapeutics Inc	2,060,552.63	$ 78.301 Million	38
Zevra Therapeutics Inc	2,036,360.66	$ 124.218 Million	61
Elutia Inc	1,917,076.92	$ 49.844 Million	26
Fortress Biotech Inc	1,653,051.28	$ 128.938 Million	78
Pulmatrix Inc	1,612,500.00	$ 3.225 Million	2
Exelixis Inc	1,601,241.50	$ 1,836.624 Million	1,147
Xoma Royalty Corporation	1,423,714.29	$ 19.932 Million	14
Q32 Bio Inc	1,385,125.00	$ 33.243 Million	24
Petros Pharmaceuticals inc	1,289,601.00	$ 3.869 Million	3
Theravance Biopharma inc	1,272,677.78	$ 114.541 Million	90
Coherus Oncology inc	1,267,115.65	$ 186.266 Million	147
Rafael Holdings Inc	1,224,608.70	$ 28.166 Million	23
Catalyst Pharmaceuticals Inc	1,216,060.44	$ 221.323 Million	182
Tg Therapeutics Inc	1,157,634.09	$ 461.896 Million	399
Glucotrack Inc	1,125,933.33	$ 16.889 Million	15
Ironwood Pharmaceuticals inc	1,021,760.00	$ 102.176 Million	100
Silexion Therapeutics Corp	922,142.86	$ 12.910 Million	14
United Therapeutics Corporation	919,571.43	$ 1,287.400 Million	1,400
Emmis Acquisition Corp	906,895.50	$ 1.814 Million	2
Halozyme Therapeutics Inc	824,687.94	$ 348.843 Million	423
Prestige Consumer Healthcare Inc	785,608.77	$ 447.797 Million	570
Agenus Inc	771,518.52	$ 62.493 Million	81
Krystal Biotech Inc	762,813.56	$ 225.030 Million	295

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.